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Abstract
Background: To evaluate acute toxicity endpoints in a cohort of patients receiving head and neck radiation with
proton therapy or intensity modulated radiation therapy (IMRT).
Methods: Forty patients received comprehensive head and neck radiation including bilateral cervical nodal
radiation, given with or without chemotherapy, for tumors of the nasopharynx, nasal cavity or paranasal sinuses,
any T stage, N0-2. Fourteen received comprehensive treatment with proton therapy, and 26 were treated with
IMRT, either comprehensively or matched to proton therapy delivered to the primary tumor site. Toxicity endpoints
assessed included g-tube dependence at the completion of radiation and at 3 months after radiation, opioid pain
medication requirement compared to pretreatment normalized as equivalent morphine dose (EMD) at completion
of treatment, and at 1 and 3 months after radiation.
Results: In a multivariable model including confounding variables of concurrent chemotherapy and involved nodal
disease, comprehensive head and neck radiation therapy using proton therapy was associated with a lower opioid
pain requirement at the completion of radiation and a lower rate of gastrostomy tube dependence by the
completion of radiation therapy and at 3 months after radiation compared to IMRT. Proton therapy was associated
with statistically significant lower mean doses to the oral cavity, esophagus, larynx, and parotid glands. In subgroup
analysis of 32 patients receiving concurrent chemotherapy, there was a statistically significant correlation with a
greater opioid pain medication requirement at the completion of radiation and both increasing mean dose to the
oral cavity and to the esophagus.
Conclusions: Proton therapy was associated with significantly reduced radiation dose to assessed non-target normal
tissues and a reduced rate of gastrostomy tube dependence and opioid pain medication requirements. This warrants
further evaluation in larger studies, ideally with patient-reported toxicity outcomes and quality of life endpoints.
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Background
Head and neck radiotherapy is associated with signifi-
cant acute and late toxicities including mucositis, taste
perversion, dysphagia, odynophagia, weight loss, and xer-
ostomia [1–3]. Improvements in radiation dose distribu-
tion, specifically the development of intensity modulated
radiation therapy (IMRT), have improved the therapeutic
ratio of treatment by reducing the incidence of toxicity
through selective sparing of specific organs at risk, such as
the parotid glands [4]. In multiple studies, more severe
treatment toxicities have been correlated with increasing
dose to regions such as the floor of mouth, oral cavity,
submandibular glands, parotid glands, area postrema of
the brainstem, and other sites [5–9], providing compelling
evidence that optimized dose distributions translate into
clinical toxicity reductions.
Proton therapy is a modality of radiation therapy dis-
tinguished from X-ray modalities by the Bragg peak,
which allows the radiation to penetrate in to the depth
of the target and then terminate, sparing normal tissues
beyond the target from unnecessary radiation [10]. This
has been hypothesized to improve the therapeutic ratio
of treatment in a number of disease sites [11].
To quantify potential objective differences in acute
toxicity, we reviewed our experience in treatment of pa-
tients with paranasal sinus and nasopharyngeal tumors
receiving comprehensive head and neck radiation ther-
apy using one of three techniques: IMRT, protons to
the primary tumor site with concurrent matched IMRT
to the neck, or comprehensive head and neck proton
therapy alone.
Methods
In this institution review board approved retrospective
study, we evaluated patients treated between 2010 and
2014 at Indiana University Health University Hospital
or affiliated sites in Indianapolis and the now-closed
Indiana University Health Proton Therapy Center in
Bloomington for primary malignancy of the nasophar-
ynx, nasal cavity or paranasal sinuses, any T stage, N0-
2 receiving radiation either definitively or following
surgery, given with or without chemotherapy, who re-
ceived radiation to the primary tumor site and bilateral
cervical lymph node regions. Patients with a prior his-
tory of head and neck radiation or with a second con-
comitant active malignancy were excluded.
Between 2010 and 2014, 12 patients received compre-
hensive head and neck radiation with IMRT in Indian-
apolis. These patients did not receive proton therapy
because either the patient faced logistical difficulties in
arranging for daily travel or temporary relocation to our
geographically distant proton treatment site (n = 8), or
the attending physician did not discuss proton therapy
as a treatment option (n = 4).
Between March 2010 and November 2012, 14 patients
were treated in Bloomington with proton therapy to the
primary tumor site with concurrent matched photon
therapy to bilateral cervical lymph node regions, as pre-
viously reported in other experiences [12–14]. IMRT
was used to treat the cervical lymphatics, with a half-
beam block at the matchline. Two matchline positions
were placed at the inferior extent of the clivus 0.5 cm
apart, and setup altered between the two matchlines
every day. The rationale in utilizing proton therapy to
the primary tumor site was related to the proximity of
the primary tumor or tumor bed to critical normal
structures, and matched photon therapy was utilized for
nodal irradiation consistent with other institutional ex-
periences [12–14] and based on a belief that compre-
hensive nodal irradiation with proton therapy would be
too time consuming or associated with minimal dosi-
metric gain. Our subjective experience was that acute
toxicity was similar to patients treated with IMRT, and
the practice of concurrent matched modalities too
complex, requiring substantial additional resources in-
cluding quality assurance.
In December 2012, in an effort to streamline patient
care and potentially reduce toxicities, we developed a
technique for comprehensive head and neck radiation
using only proton therapy and implemented that in our
practice, treating 14 patients meeting study inclusion
criteria between 2012 and 2014. This technique has
previously been described in detail [15]. With the im-
plementation of comprehensive proton therapy, we did
not treat with matched IMRT again.
Patient and treatment factors collected were age, gen-
der, T and N stage, Karnofsky performance status prior
to treatment, treatment modality, indication for radi-
ation (definitive or adjuvant), incorporation of a neck
dissection, prescribed radiation dose to the neck and to
the primary tumor site, utilization of chemotherapy,
type of chemotherapy, placement of a gastrostomy tube
(g-tube) during treatment, whether the patient became
g-tube dependent (defined as no more than sips of
water by mouth) by the completion of treatment,
whether they were g-tube dependent 3 months follow-
ing completion of treatment, patient weight prior to initi-
ation of treatment and each week during radiation, as well
as at 1 and 3 months after completion of radiation, and
opioid pain requirements. Opioid pain medication usage
was converted to a daily equivalent morphine dose (EMD)
[16]. The patient’s EMD prior to initiation of radiation
served as the baseline and changes in the opioid medica-
tion usage were recorded each week during radiation, and
at 1 and 3 months following completion of therapy. Due
to variable documentation by different treating physi-
cians, provider-assessed toxicity assessments were not
uniformly available.
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Our institutional approach for head and neck patients
has been to recommend upfront placement of gastros-
tomy tubes, particularly for those receiving concurrent
chemotherapy, although some patients decline and prefer
a reactive approach. With the development of comprehen-
sive proton therapy at the proton therapy center, the im-
proved radiation dosimetry to the oral cavity, esophagus
and larynx prompted a shift to a generally reactive policy
of gastrostomy tube placement for those who demon-
strated a clinical need. One proton patient had a gastros-
tomy tube placed prior to radiotherapy at the time of
surgical resection with free flap reconstruction. One
proton patient with esthesioneuroblastoma and bilateral
retropharyngeal nodal involvement had a prophylactic
gastrostomy tube placed due to concern for toxicity re-
lated to delivery of concurrent cisplatin and etoposide
[17]. None of the patients treated with comprehensive
proton therapy required placement of a gastrostomy
tube during radiotherapy. All patients were evaluated
by a dietician during treatment and provided with sup-
plemental and meal replacement nutritional shakes at
no cost.
Dosimetric information was exported from individual
treatment plans for the following organs at risk (OARs):
the esophagus (contoured from the cricoid to the cau-
dal aspect of the aortic arch), the larynx (inclusive of
the thyroid cartilage and postcricoid space abutting the
vertebral body), the parotid glands (separated as the
“better-spared” and “lesser-spared” glands), and the
“oral cavity”, an avoidance structures whose lateral and
anterior border was defined by the mandible, cranial by
the maxillary bone and inclusive of any air cavity above
the oral tongue, inferior including the floor of mouth,
and posterior including the base of tongue. In some pa-
tients, regional nodal involvement or primary tumor
extent precluded any ipsilateral parotid gland sparing,
so not every patient had a “lesser-spared” parotid gland.
For the purpose of this study, patients were grouped
according to the radiation modality used to treat the cer-
vical lymphatics, so that those treated with comprehen-
sive IMRT and those treated with IMRT to the neck
matched to proton therapy to the primary site were
combined for comparison against comprehensive proton
therapy. To assess the validity of this grouping, we eval-
uated the mean dose to assessed OARs for patients re-
ceiving IMRT either alone or matched to proton therapy
to the primary tumor site (Table 1). For patients with
node negative disease, those treated with matched IMRT
had reduced oral cavity radiation dose compared to
those treated with comprehensive IMRT (mean 28.3 ver-
sus 44.4 Gy, P = 0.036). There was no statistically signifi-
cant difference in mean dose to other assessed OARs.
Statistical analysis was conducted using SAS version
9.3 (Cary, NC). The significance level was set at 0.05.
Descriptive statistics for each variable were reported. For
the two cohorts of proton and IMRT nodal irradiation,
univariate association of categorical variables was assessed
with the Fisher exact test, and the Mann-Whitney U test
for numerical covariates. The use of concurrent chemo-
therapy and the presence of cervical nodal disease (N+)
were considered as clinically important confounders for
inclusion in multivariable analysis of toxicity outcomes.
The adjusted association between treatment modality and
each toxicity outcome was estimated by exact logistic re-
gression and linear regression for binary and numerical
outcome respectively. The normality assumption was
checked by residual plots. Due to a large number of pa-
tients with zero opioid pain medication requirements over
time, the model assumptions of linear regression were vio-
lated, prompting alternate binary analysis using categories
of opioid pain medication greater than baseline or the
same or less than baseline requirement.
A subset analysis was performed of patients receiving
concurrent chemotherapy in which Spearman’s rank cor-
relation coefficient was used to assess for correlation
between assessed continuous dosimetric variables and
toxicity endpoints.
Results
Forty patients met the inclusion criteria for this study.
Table 2 reviews patient characteristics and treatment
details, comparing those who received neck irradi-
ation with IMRT and those with comprehensive ir-
radiation using only proton therapy. There were
Table 1 Comparison of mean dose to organs at risk for IMRT delivered alone or matched to proton therapy to the primary tumor
site
Node negative Node positive
Organ at risk Alone (n = 2) Matched (n = 8) P Alone (n = 10) Matched (n = 6) P
Oral Cavity 44.4 28.3 0.036 47.6 39.7 0.093
Larynx 46.3 38.9 0.117 43.5 46.2 0.492
Esophagus 26.0 29.4 0.296 35.6 36.8 0.562
Better spared parotid 31.6 26.5 0.192 32.9 35.3 >0.99
Lesser spared parotid 29.5 (n = 1) 28.8 (n = 8) N/A 35.7 (n = 3) 37.2 (n = 3) >0.99
IMRT intensity modulated radiation therapy, radiation dose expressed in Gy
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Table 2 Patient and treatment characteristics
Variable IMRT neck (n = 26) Proton neck (n = 14) P Comparison
Median age (range) 54.1 (22–77) 46.7 (16–71) 0.98
Gender
Male 14 (53.8 %) 11 (78.6 %) 0.18
Female 12 (46.2 %) 3 (21.4 %)
Primary tumor site
Nasopharynx 15 (57.7 %) 2 (14.3 %) 0.02
Nasal/Paranasal 11 (42.3 %) 12 (85.7 %)
Tumor Histology
SCC 13 (50.0 %) 3 (21.4 %) 0.19 SCC vs non-SCC
Poorly differentiated carcinoma 5 (19.2 %) 0
Sinonasal undifferentiated 4 (15.4 %) 5 (35.7 %)
Esthesioneuroblastoma 1 (3.8 %) 5 (35.7 %)
Neuroendocrine carcinoma 1 (3.8 %) 0
Lymphoepithelioma 1 (3.8 %) 1 (7.1 %)
High grade mucoepidermoid carcinoma 1 (3.8 %) 0
KPS before radiation
90–100 13 (50 %) 9 (64.3 %) 0.51 ≥90 vs <90
80 9 (34.6 %) 3 (21.4 %)
70 4 (15.4 %) 2 (14.3 %)
T stage
T4 13 (50 %) 11 (78.6 %) 0.10 T4 vs < T4
T3 8 (30.8 %) 2 (14.3 %)
T2 4 (15.4 %) 1 (7.1 %)
T1 1 (3.8 %) 0
N Stage
N0 10 (38.5 %) 10 (71.4 %) 0.09 N0 vs N+
N1 5 (19.2 %) 1 (7.1 %)
N2 11 (42.3 %) 3 (21.4 %)
Neck dissection
Upfront 0 1 (7.1 %) 0.54 none vs other
None 25 (96.2 %) 12 (85.7 %)
Adjuvant/Salvage 1 (3.8 %) 1 (7.1 %)
Chemotherapy sequencing
None 3 (11.5 %) 2 (14.3 %) 0.10 concurrent vs other
Induction 0 3 (21.4 %)
Concurrent 23 (88.5 %) 7 (50.0 %)
Concurrent and adjuvant 0 2 (14.2 %)
Chemotherapy Type
Cisplatin 15 (57.7 %) 6 (42.9 %) 0.14 cisplatin vs non-cisplatin
Cisplatin and etoposide 1 (3.8 %) 5 (35.7 %)
Cisplatin, docetaxel, fluorouracil 2 (7.7 %) 1 (7.1 %)
Carboplatin 2 (7.7 %) 0
Carboplatin + taxol 1 (3.8 %) 0
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imbalances between the two groups in several areas,
with the proton cohort having more paranasal sinus
primaries and a greater use of induction chemother-
apy. Although not statistically significant in this sam-
ple size, the proton cohort had a greater percentage
of T4 and N0 tumors.
Figure 1 shows mean dose volume histograms for the
assessed OARs by treatment modality, with 95 % confi-
dence intervals, separated by patients treated for N0 ver-
sus N+ disease. Table 3 reports comparisons of the
mean of the mean dose to OARs by treatment modality,
separated for patients with N0 versus N+ disease. For
patients with node positive disease, regional nodal dis-
ease precluded sparing of one parotid gland in 3 of 4
proton patients and 10 of 16 IMRT patients, precluding
statistical dosimetric comparison of the “lesser-spared”
parotid in the node positive subgroup. Table 4 reviews
the association of treatment modality with toxicity out-
comes in univariate analysis.
Table 5 reviews multivariable analysis outcomes by
exact logistic regression for binary toxicity outcomes
in a model including treatment modality and con-
founding variables of concurrent chemotherapy and
the presence of cervical nodal disease. Both treatment
modality and concurrent chemotherapy had a statisti-
cally significant association with g-tube dependence at
the completion of radiation, while only treatment mo-
dality had an association with g-tube dependence at
3 months after radiotherapy. Only treatment modality
had a statistically significant association with EMD use
greater than baseline at completion of treatment.
There were no variables with a statistically significant
association with EMD greater than baseline at 1 and
3 months after radiation. There were no variables with
a statistically significant association with percent
weight loss at completion of radiation, or at 1 or
3 months after radiation.
In a subgroup analysis of the 32 patients receiving
concurrent chemotherapy, there was a statistically
significant correlation with a greater opioid pain
medication requirement at the completion of radi-
ation and both increasing mean dose to the oral cav-
ity (Spearman’s ρ = 0.502, P = 0.003) and increasing
mean dose to the esophagus (ρ = 0.361, P = 0.042).
There was a positive correlation between increasing
percent weight loss at the completion of treatment
and increased opioid pain medication requirement
(ρ = 0.419, P = 0.017).
Discussion
Acute toxicity during head and neck radiotherapy re-
mains significant despite advances in radiation treatment
planning and delivery [1, 3]. Based on improvements in
radiation dosimetry compared to IMRT that are antici-
pated to translated into reduced clinical toxicities, pro-
ton therapy has been proposed as a treatment modality
for head and neck radiation [18], although the cost of
proton therapy is generally greater than that of IMRT;
approximately 2.4 times the cost of IMRT [19]. Because
proton therapy is more resource-intensive and more
limited in availability than photon-based treatments,
additional clinical data are needed to quantify the po-
tential benefit of proton therapy in head and neck
treatments. We hope that our initial experience and
data may serve in hypothesis formation for further
investigation.
Oral mucositis in particular is an often severe [20] and
costly [21, 22] toxicity of treatment associated with poor
Table 2 Patient and treatment characteristics (Continued)
Cetuximab 2 (7.7 %) 0
Smoking history
Never 11 (42.3 %) 10 (71.4 %) 0.18 never vs any history
< 10 pack years 1 (3.8 %) 0
> 10 pack years 14 (53.8 %) 4 (28.6 %)
Active smoking at time of radiation 6 (23.1 %) 2 (14.3 %) 0.69
Diabetes Mellitus 4 (15.4 %) 0 0.28
Gastrostomy tube placement 22 (84.6 %) 2 (14.3 %) <0.001
Median primary tumor dose 71.8 Gy 71.4 Gy (RBE) 0.86
Range primary dose 66–76.4 Gy 63–75.6 Gy (RBE)
Median neck dose, node negative 52.3 Gy 50.2 Gy (RBE) 0.58
Range neck dose, node negative 40.0–59.4 Gy 45.0–58.0 Gy (RBE)
Median neck dose, node positive 68.3 Gy 72.9 Gy (RBE) 0.06
Range neck dose, node positive 59.4–70.29 Gy 70.0–75.6 Gy (RBE)
SCC squamous cell carcinoma, vs versus, KPS Karnofsky performance status, RBE relative biological effectiveness
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pain control despite near universal opioid pain require-
ments [20, 23]. Although chemotherapy is an independent
risk factor for mucositis, radiation dose to the oral cavity
is associated with the incidence and severity of mucositis
[6], xerostomia [24], and long-term dysphagia [25], and re-
ducing or avoiding radiation exposure to the mucosa
would seem the most direct means of reducing or avoid-
ing mucositis. In our proton cohort, significant sparing of
the oral cavity was achieved, with a mean dose of 5.1 Gy
(RBE) in node negative patients and 8.5 Gy (RBE) in node
positive patients. Figure 2 shows an example of oral cavity
sparing in a patient irradiated with involved nodal disease.
Similar oral cavity sparing and mean oral cavity doses have
been reported by others using spot-scanning proton ther-
apy in comparative treatment planning for patients receiv-
ing ipsilateral head-and-neck radiation [26] and in clinical
results of multi-field optimized intensity modulated pro-
ton therapy in nasopharyngeal cancer [27]. The observa-
tions of our proton cohort are in line with a retrospective
study of proton therapy versus mixed photon-electron
radiotherapy for pediatric salivary tumors, which found
proton therapy was associated with reduced radiation dose
to the oral cavity and reduced incidence of grade 2–3 oral
mucositis [28].
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Node Negative: Oral Cavity Node Negative: Larynx Node Negative: Esophagus
Node Positive: Oral Cavity
Node Negative: Better Spared Parotid Node Positive: Better Spared Parotid Node Negative: Less Spared Parotid
Node Positive: EsophagusNode Positive: Larynx
Fig. 1 Mean dose volume histograms (DVHs) to organs at risk by radiation treatment modality, separated by node negative and node positive
patients. The mean DVH is presented with 95 % confidence intervals
Table 3 Comparison of mean dose to organs at risk by radiation modality when IMRT or proton therapy was used for treatment of
the cervical lymph nodes
Node negative Node positive
Organ at risk IMRT (n = 10) Proton (n = 10) P IMRT (n = 16) Proton (n = 4) P
Oral cavity 31.5 5.1 <0.001 44.6 8.5 <0.001
Larynx 40.4 16.8 <0.001 44.5 21.4 0.002
Esophagus 28.7 5.9 <0.001 36.0 12.1 <0.001
Better spared parotid 27.5 15.4 <0.001 33.8 17.4 0.001
Lesser spared parotid 29.5 (n = 9) 19.0 (n = 10) 0.006 35.5 (n = 6) 18.4 (n = 1) N/A
IMRT intensity modulated radiation therapy, Radiation dose expressed in Gy for IMRT and Gy (RBE) for proton therapy
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Opioid pain medication is often required for symp-
tomatic management of head and neck cancer patients
receiving radiation. The overall opioid pain require-
ments of our IMRT cohort are consistent with the opi-
oid pain utilization rates reported elsewhere in the
literature [20, 23], in contrast to the markedly lower
rate of change in opioid requirements in our proton co-
hort by the completion of treatment and at 1 month
post radiation. While increased opioid requirements in
response to acute toxicities are temporary in most pa-
tients (reflected by a majority of patients returning to
baseline EMD by 3 months post radiation), opioids are
associated with many adverse effects including somno-
lence, nausea, dry mouth, anorexia, and constipation
[29], as well as drug interactions and risk of overdose
and death [30]. Opioid-related adverse effects and
events are associated with significant economic costs
[31] in addition to the cost of the medications
themselves and out-of-pocket expenses, which can pose
a significant economic burden to patients [32].
Our institutional approach has been to recommend
prophylactic g-tube placement for patients receiving
IMRT, but we instituted a reactive approach for those
receiving comprehensive proton therapy, none of whom
required placement of a gastrostomy tube during proton
therapy. Although there was a statistically significant dif-
ference in the rate of placement of g-tube between co-
horts, as shown in Table 5, this comparison is less
informative because of the differing approach to g-tube
placement. For this reason we chose to evaluate and
compare the rate of g-tube dependence during and after
therapy. The rate of g-tube dependence in our proton
cohort was very low, with no patients being g-tube
dependent at the completion of radiation or at 3 months
after radiation. In contrast, the significantly higher rates
of g-tube dependence seen in our IMRT cohort are in
Table 5 Multivariable analysis of binary outcomes
Outcome Model predictors Level Odds ratio (95 % CI) P
G-tube dependent at completion of RT RT Modality proton vs IMRT 0.03 (<0.01–0.15) <0.001
Nodal status N0 vs N+ 0.58 (<0.01–9.07) >0.99
Concurrent chemo yes vs no 12.4 (1.74– > 9999) 0.033
G-tube dependent 1 month after RT RT Modality proton vs IMRT 0.11 (<0.01–0.61) 0.028
Nodal status N0 vs N+ 0.88 (0.11–6.78) >0.99
Concurrent chemo yes vs no 2.97 (0.42– > 9999) 0.375
EMD > baseline at completion of RT RT Modality proton vs IMRT 0.09 (0.01–0.57) 0.006
Nodal status N0 vs N+ 0.92 (0.11–6.07) >0.99
Concurrent chemo yes vs no 4.2 (0.39–66.1) 0.375
CI confidence interval, G-tube gastrostomy tube, RT radiation therapy, IMRT intensity modulated radiation therapy, chemo chemotherapy P values <0.05 are
in bold.
Table 4 Univariate analysis of patient and treatment factors and toxicity endpoints at each time point
G-tube
dependent
Median change EMD EMD > baseline Median % weight
loss
>10 % weight loss
Variable Comp 3 mo Comp 1 mo 3 mo Comp 1 mo 3 mo Comp 1 mo 3 mo Comp 1 mo 3 mo
Age 0.65 0.86 0.59 0.76 0.31 0.26 0.64 0.68 0.31 0.89 0.92 0.06 0.42 0.67
Gender >0.99 0.73 0.80 0.37 0.19 0.75 >0.99 0.72 0.65 0.84 0.42 0.72 0.75 0.19
Tumor site (NPx vs nasal/paranasal) 0.003 0.15 0.08 0.33 0.96 0.10 0.52 >0.99 0.17 0.19 0.29 >0.99 0.11 0.05
Histology (SCC vs non-SCC) 0.20 0.17 0.037 0.17 0.44 0.05 0.11 0.71 0.16 0.16 0.27 >0.99 0.20 0.34
T stage (T4 vs other) 0.52 0.30 0.051 0.19 0.71 0.007 0.11 0.44 0.18 0.13 0.21 0.12 0.053 0.025
N stage (N0 vs other) 0.21 0.48 0.17 0.024 0.19 0.33 0.75 >0.99 0.14 0.43 0.64 0.45 0.20 0.33
KPS (≥90 % vs <90 %) 0.06 0.04 0.44 0.40 0.49 0.20 0.34 0.05 0.33 0.27 0.68 >0.99 0.52 0.34
Chemotherapy (concurrent vs other) 0.004 0.08 0.033 0.15 0.38 0.042 0.05 0.66 0.007 0.09 0.96 0.66 0.11 0.11
Smoking history (none vs other) 0.11 0.08 0.014 0.33 0.85 0.027 0.20 0.27 0.05 0.16 0.36 >0.99 0.34 0.05
Active smoking at time of RT >0.99 0.66 0.20 0.34 0.78 0.44 0.43 0.35 0.13 0.78 0.83 0.35 0.70 0.69
Diabetes mellitus 0.60 0.18 0.25 0.81 >0.99 0.26 0.58 0.55 >0.99 0.63 0.63 0.55 0.57 0.55
Modality (proton vs IMRT neck) <0.001 0.004 <0.001 0.12 0.49 <0.001 0.046 0.12 0.07 0.13 0.15 0.45 0.09 0.020
EMD equivalent morphine dose, Comp at completion, NPx nasopharynx, SCC squamous cell carcinoma, KPS Karnofsky Performance Status, RT radiation therapy,
IMRT intensity modulated radiation therapy P values <0.05 are in bold.
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line with multi-institutional data on the rates of g-tube
dependence in T3 and T4 oropharyngeal patients receiv-
ing IMRT with or without concurrent chemotherapy
[33]. Our results are similar to matched case control
clinical data in patients treated for nasopharynx cancers,
in which intensity modulated proton therapy was associ-
ated with a reduced need for gastrostomy tube place-
ment during radiation compared to IMRT [27].
Although weight loss during and after radiation is
common in patients treated for head and neck cancers,
the median weight loss and significant weight loss >10 %
were both fairly high in our patients. Significant weight
loss has been reported in one-third to one-half of
head and neck patients receiving radiation in the era
prior to IMRT [34], while 12.6 % were reported to
have lost >10 % weight in a series of patients receiv-
ing mostly IMRT [35]. Conversely, median weight loss
during treatment was a low 2.8 % in a retrospective
series of 50 patients with stage III and IV head and
neck cancers receiving chemoradiation with IMRT
[36]. Several variables are associated with weight loss
during radiation, but among treatment factors, the
use of concurrent chemotherapy is strongly associated
with an increased risk of clinically significant weight
loss [35]. In a multivariable model accounting for
concurrent chemotherapy and node positive disease,
we found no statistical difference by treatment modal-
ity in weight loss at the completion of treatment, or
at 1 or 3 months post radiation. This may reflect the
successful use of gastrostomy tubes to maintain
weight or limit weight loss. However, the placement
of g-tubes is associated with additional risks and
costs, with a reported major complication rate of 7–
10 % [37, 38]. As others have reported, when consid-
ering the “true” cost of different technologies over the
full care cycle, including the potential reductions in
costs related to reduced g-tube placement, attendant
hospitalization, supplemental nutrition, opioid pain
Fig. 2 An example of a patient irradiated with bilateral involved cervical nodes. The involved lymph nodes are contoured in red. The prescription
dose to the gross nodal disease was 70 Gy (RBE) in 35 fractions. Using a combination of posterior-anterior and posterior oblique fields, significant
oral cavity sparing was achieved by virtue of the finite range of each proton beam
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medication and associated complications, proton ther-
apy can be cost competitive or provide higher-value
care compared to IMRT [39]. Additional clinical data
are needed to build more robust models of the care
cycle costs of competing radiation modalities that in-
corporate the costs related to treatment toxicities and
failures in head and neck cancer.
Our data analysis is a retrospective comparison of pa-
tients who were not randomized to treatment modality.
In addition to unidentified or unknown potential selec-
tion biases inherent in retrospective analysis, as may be
expected from a small cohort, there were imbalances be-
tween cohorts in patient characteristics and treatment
parameters, which may be associated with toxicities. The
limited sample size limits the statistical power to assess
for or control all potential variables that may be associ-
ated with toxicities. Although one could speculate that
the IMRT plans could have been further optimized, the
mean dose to the larynx and esophagus in the IMRT co-
hort readily met the constraints recommended in the
Radiation Therapy Oncology Group 0615 phase II trial
in nasopharynx cancer [40], the oral cavity mean dose
fell close to (node positive) or below (node negative)
proposed oral cavity constraints [24], and the “better”
spared parotid gland mean dose with IMRT was close to
a standard mean dose objective [41]. The magnitude of
dose sparing to OARs with proton therapy in compari-
son to IMRT in our cohorts reflects “real-world” gains
in patients treated in an academic healthcare setting,
but in-silico treatment planning comparisons of ideal-
ized dose distributions have also demonstrated proton
therapy OAR sparing relative to IMRT in head and
neck cancer [15, 26].
Conclusions
In a multivariable model including confounding vari-
ables of concurrent chemotherapy and involved nodal
disease, proton therapy was associated with a lower
opioid pain requirement at the completion of radiation
and a lower rate of gastrostomy tube dependence by
the completion of radiation therapy and at 3 months
after radiation. Compared to IMRT, comprehensive
head and neck radiation therapy with proton therapy
for nasopharynx, nasal and paranasal sinus tumors was
associated with significantly lower mean doses to the
oral cavity, esophagus, larynx, and parotid glands in
both node negative patients and those with involved
nodal disease.
Acknowledging the limitations of this study, our find-
ings, together with those of other studies [27, 28], of im-
proved oral cavity sparing, a reduced rate of g-tube
dependence, and reduced opioid pain medication require-
ments using proton therapy merit further evaluation in a
larger study with more uniform patient and treatment
characteristics, and inclusion of patient-reported toxicity
outcomes and quality of life endpoints.
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